Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Vasomax completes phase II in Germany

May 24, 1996

MacroChem's erectile dysfunction therapy moves to phase I/II in U.S.

May 24, 1996

Takeda claims antidiabetic and hypolipidemic agents

May 24, 1996

Role of p140 in diabetes investigated by Ono

May 24, 1996

PolyHeme phase II results in trauma patients announced

May 24, 1996

RF-1051 receives orphan drug status in PWS

May 24, 1996

Amgen begins clinical testing of leptin

May 24, 1996

Intrachol receives U.S. patent protection

May 24, 1996

Orphan Medical discontinues glucaric acid development

May 24, 1996

Zoledronate effective in Paget's disease patients

May 24, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...